Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008033 | 0.86 | RAB9A (0.54) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL24362149 | 0.85 | HPGD (0.47) | MIFRXFP1NQO2NPC1RAB9A | |
| SCHEMBL29618957 | 0.85 | HPGD (0.47) | MIFRXFP1NQO2NPC1RAB9A | |
| SCHEMBL4612314 | 0.84 | CA12 (0.48) | RXFP1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL486774 | 0.84 | RXFP1 (0.42) | CXCR1MIFRXFP1NQO2NPC1 | |
| SCHEMBL18703190 | 0.83 | MAPT (0.57) | RXFP1MAPTGPR119NPC1RAB9A | |
| SCHEMBL25610019 | 0.83 | MAPT (0.40) | RXFP1MAPTGPR119NPC1RAB9A | |
| SCHEMBL29803200 | 0.83 | MAPT (0.57) | RXFP1MAPTGPR119NPC1RAB9A | |
| SCHEMBL1007327 | 0.83 | MAPT (0.49) | MAPTRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24253966 | 0.83 | POLB (0.56) | RXFP1MAPTRAB9AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609080-B2 | Methods and compositions for controlled release of drugs | THE UNIVERSITY OF WYOMING (US) | 2013-12-17 | — | — | US | disclosed |
| US-20120148521-A1 | Methods and Compositions for Controlled Release of Drugs | THE UNIVERSITY OF WYOMING | 2012-06-14 | — | — | US | disclosed |
| US-20120148521-A1 | Methods and Compositions for Controlled Release of Drugs | THE UNIVERSITY OF WYOMING | 2012-06-14 | — | — | US | disclosed |
| US-20120148521-A1 | Methods and Compositions for Controlled Release of Drugs | THE UNIVERSITY OF WYOMING | 2012-06-14 | — | — | US | disclosed |
| US-8105570-B2 | Covalently bond to polymer or other moiety that blocks activity until reaching delivery site; not easily circumventable | THE UNIVERSITY OF WYOMING (US) | 2012-01-31 | — | — | US | disclosed |
| US-8105570-B2 | Covalently bond to polymer or other moiety that blocks activity until reaching delivery site; not easily circumventable | THE UNIVERSITY OF WYOMING (US) | 2012-01-31 | — | — | US | disclosed |
| US-8105570-B2 | Covalently bond to polymer or other moiety that blocks activity until reaching delivery site; not easily circumventable | THE UNIVERSITY OF WYOMING (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1501352-A4 | METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE OF DRUGS | UNIV WYOMING (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1501352-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE OF DRUGS | THE UNIVERSITY OF WYOMING (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20050002895-A1 | Methods and compositions for controlled release of drugs | WYOMING, UNIVERSITY OF, THE | 2005-01-06 | — | — | US | disclosed |
| WO-2003051113-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE OF DRUGS | THE UNIVERSITY OF WYOMING (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050002895-A1 | Methods and compositions for controlled release of drugs | OPRK1, OPRM1, OPRL1 | CXCR1 3345/4885MIF 1963/4885RXFP1 3198/4885 |
| US-20120148521-A1 | Methods and Compositions for Controlled Release of Drugs | OPRK1, OPRM1, AANAT | CXCR1 4629/4885MIF 2088/4885RXFP1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.